CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India Max Neeman International is the only CRO in India to manage hemophilia trials according to the Clinical Trials Registry-India (CTRI). Of the total hemophilia trials currently being conducted in India, Max Neeman can boast supporting 80% of these with the ...
Max Neeman International ISO 14155: 2011 Certified for Medical Device Trials Max Neeman announces the grant of ISO 14155:2011 certificate; the only Indian CRO and one of only a few global CROs to be certified for design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety ...
Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study Current Ph IV success and activities are due to a specific business model Max Neeman created for such \'Observational studies\' based on over 10 years of experience. Segments of the business model include: zonal stratification of >1000 sites and SOPs to imp...
Max Neeman International Responds to New India Clinical Research Guidelines RESEARCH TRIANGLE PARK, N.C., May 3, 2011 /PRNewswire/ -- The Drug Controller General of India (DCGI) has formed new Regulatory and ICH GCP guidelines. These guidelines include: recommendations regarding structure and format of genomic biomarker regulato...
Max Neeman International Launches Customized Project Management Software for India-based Clinical Studies Max Neeman International, creates and launches customized Project Management Software (PMS) to meet unique study needs and client demands....
Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery Max Neeman International, leading Indian CRO, is part of the prestigious Max Group whose sister-company, Max Healthcare recently had one of 12 hospitals, \'Max Institute of Minimal Access, Metabolic & Bariatric Surgery\' accredited as a Center of Excellence...
Max Neeman Develops Innovative Approach for Rare Disease Studies Max Neeman is a leading CRO in India that has a focus on Rare Disease Studies, in addition to other indications. Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number an...
Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2011 /PRNewswire/ -- India\'s premier CRO, Max Neeman, participated in the 59th annual Neurological Society of India & Congress of Neurological Surgeons (NEUROCON) held in Jaipur, India this past December. ...
Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed...
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. ...
Indias Favorable and Progressive Regulatory Environment Causes Accelerated Growth of Max Neeman Internationals Regulatory Services India has evolved into a preferred destination for conducting clinical trials in large part because the Indian Regulatory bodies have created an environment which is focused on quality, transparency and protection in research activities. Regulatory stand...
Chief Operating Officer of Leading India-based CRO, Max Neeman International Featured as One of Indias Top 10 Women Achievers in Life Sciences Industry Max Neeman International announced today that Dr. Renu Razdan has been featured in the November issue of BioSpectrum India as a prominent female achiever in the Life Sciences community with valuable guidance as to what it takes to be a leader. Her insigh...
Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems This updated certification of the world renowned British Standard for Information Security Management Systems (BS 7799-2:2002) is the standard outlining requirements for an Information Security Management System (ISMS). An ISMS helps in designing; impleme...
Over 200 Studies Awarded to India-Based CRO Max Neeman International Max Neeman International, India\'s premier CRO, has quadrupled the amount of clinical trials awarded since 2007 and reached the milestone of over 200 in 2010. Per CEO, Dr. Ajoy Kumar, Focused areas of specialty, unique offerings, customer service and cons...
Max Neeman International Continues to Expand in Response to Increased Client Demand for Medical Writing Services Max Neeman International, India\'s premier CRO, has expanded its team of medical writers in response to the growing demand for medical writing services. The team consists of highly qualified medical writers with scientific or medical educations and clinic...
Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model Max Neeman International, India\'s premier CRO, created a niche in Data Management services and has extended the platform to provide expert CDISC (Clinical Data Interchange Standards Consortium) services and modified solutions which include on-going and le...
Max Neeman International Sets Up an Exclusive Team for Cosmetic Studies Expanding Upon Dermatology Experience RESEARCH TRIANGLE PARK, N.C., June 14 /PRNewswire/ -- Max Neeman International, India\'s premier CRO, has entered into the cosmetics arena as this industry recognizes the Indian market potential due to favorable changes in the country\'s demographics. A ...
Max Neeman Announces Expansion of Central Lab Services in Partnership with Max Healthcare RESEARCH TRIANGLE PARK, N.C., May 25 /PRNewswire/ -- Max Neeman International, a full service Contract Research Organization announces set-up of company central lab services beginning with a Phase II study in Oncology. The India-based CRO will be respons...
Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites RESEARCH TRIANGLE PARK, N.C., May 12 /PRNewswire/ -- The International Collaborative Cancer Group, in collaboration with the Institute of Cancer Research Clinical Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES). IES is a rand...
Max Neeman International Sets Up a New Vertical for Nutraceutical Studies Research Triangle Park, NC (PR Newswire) April 26, 2010 - Max Neeman International, a leading Indian CRO, expands its list of services with the formation of an exclusive team to conduct studies on Nutraceuticals. There is an emerging trend in the Nutrace...
Max Neeman International and AMEDON Collaborate to Increase EDC Performance Max Neeman International offers additional electronic data management system in collaboration with German software company, AMEDON GmbH for enhanced and expanded Electronic Data Capture (EDC) services....
Max Neeman International has set up an exclusive team for conducting Minimally Invasive Surgery Studies in collaboration with Max Healthcare. Research Triangle Park, NC (PR Newswire) February 15, 2010 – Max Neeman International, a leading Indian CRO, has formed an exclusive team of India’s finest, most experienced Physicians to conduct Minimally Invasive Surgery Studies. The team consists of t...
Top Five Pharmaceutical Company Joins with Max Neeman on Groundbreaking Diabetes, Hypertension Prevalence Study RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- One of the top global pharmaceutical companies has initiated an observational study on the prevalence of Diabetes and Hypertension called SITE (Screening India\'s Twin Epidemics) in collaboration with Ma...
Max Neeman International Expands its Pharmacy Services Facility in Delhi Max Neeman International, a leading India based Contract Research Organization and subsidiary of the Max India group, expands its Pharmacy services facility in Delhi to over 4000 square feet...
Max Neeman to Open Phase I/IIa Unit Max Neeman, a leading Indian CRO, announced a partnership with Max Healthcare to open a Phase I/IIa clinical trial unit at Max Super Speciality Hospital, New Delhi, India. ...
